On Wednesday, Regulus Therapeutics Inc. (NASDAQ:RGLS)’s shares gained 12.48%, and closed at $17.94, after a biopharmaceutical corporation, declared recently the selection of RG-125 (AZD4076), a GalNAc-conjugated anti-miR targeting microRNA-103/107 (“miR-103/107″) for the treatment of Non Alcoholic Steatohepatitis (“NASH) in patients with type 2 diabetes/pre-diabetes, as a clinical candidate by AstraZeneca under the companies’ planned alliance to discover, develop and commercialize microRNA therapeutics. RG-125 (AZD4076) is the first compound from the alliance to be selected for clinical development by AstraZeneca. In connection with the candidate selection, AstraZeneca will pay Regulus $2.5 million and will assume development of the program following acceptance of an Investigational New Drug application. In the near term, Regulus and AstraZeneca plan to submit key preclinical data on the RG-125 (AZD4076) program to be presented at a scientific meeting later this year and expect to initiate a Phase I study of RG-125 (AZD4076) in humans by the end of 2015.
The role of miR-103/107 in insulin sensitivity and resistance was first recognized by the laboratory of Dr. Markus Stoffel, Professor of the Institute of Molecular Health Sciences at ETH Zurich and member of Regulus’ Scientific Advisory Board. In mouse models of diabetes, Regulus has demonstrated that inhibition of miR-103/107 with its anti-miRs leads to a sustained reduction in fasting glucose and fasting insulin levels. Additionally, anti-miRs targeting miR-103/107 function as unique insulin sensitizers as determined by hyperinsulinemic-euglycemic clamp, which is a robust method for assessing insulin sensitivity. Further, inhibition of miR-103/107 with Regulus’ anti-miRs decreases liver triglycerides and steatosis, providing an opportunity to investigate RG-125 (AZD4076) to treat NASH in patients with type 2 diabetes/pre-diabetes.
Regulus Therapeutics Inc., a biopharmaceutical corporation, focuses on the discovery and development of drugs that target microRNAs for the treatment of various diseases in the United States. It uses its microRNA product platform to develop anti-miRs, which are chemically modified and single-stranded oligonucleotides.
Second Sight Medical Products, Inc. (NASDAQ:EYES)’s shares jumped 10.94%, and settled at $14, during the last trading session on Wednesday, after EYES declared the first successful implant of a mechanical model of the Orion(TM) I Visual Cortical Prosthesis (“Orion I”) in an animal study.
The first implant was performed as part of a phase I pre-clinical study, which is designed to evaluate fit, form, stability and biocompatibility. This study, which is predictable to run through the end of the year, is the first major milestone in the Corporation’s development of the Orion I. Fully functional prototypes are predictable to be accomplished later this year with active animal implants planned to start by Q1 2016; the first human clinical trials are planned to commence by Q1 2017. Assuming positive initial results in patients and discussions with regulators, an expanded pivotal clinical trial for global market approvals is planned.
“This is a major milestone not only for the Corporation but, more importantly, those affected by virtually all forms of blindness,” said Robert Greenberg, M.D., Ph.D., President and CEO of Second Sight. “Following the success of Argus II in patients with Retinitis Pigmentosa, we are looking forward to extending the hope of restoring some useful vision to nearly all blind individuals with the Orion I.”
Second Sight Medical Products, Inc. develops, manufactures, and markets implantable prosthetic devices to restore functional vision to blind patients in the United States, Canada, Europe, and Saudi Arabia.
At the end of Wednesday’s trade, Organovo Holdings, Inc. (NYSEMKT:ONVO)’s shares climbed 10.46%, and closed at $4.33, as with extremely volatile equity markets numerous small cap companies have presented incredible upside opportunities for investors. However, countless companies remain unnoticed and forgotten by analysts, journalists, and investors. There are several companies that we have uncovered that merit more attention in our opinion due to underlying fundamental, industry and technical factors. Organovo Holdings, Inc. (ONVO), BIND Therapeutics, Inc. (BIND) and ForceField Energy Inc. (FNRG), despite their differing industries, present traders and investors with similar factors that are capable of providing incredible upside opportunity.
Organovo Holdings, Inc. (ONVO) has been at the business end of its therapeutic developments and recently presented data on its in vitro three-dimensional kidney tissue at the 2015 Experimental Biology conference in Boston, Massachusetts. This is a major step for the corporation which is adapting 3D printing technology to enhance and develop organ tissues. The stock is rebounding after gains achieved via its 9.25 52-week high. Recent rallies as high as 8% have ignited renewed investor interest in the corporation. With a market cap of $332M investors will be keeping a keen eye on Organovo Holdings, Inc. (ONVO).
Organovo Holdings, Inc., a development-stage corporation, focuses on developing and commercializing functional human tissues that could be employed in drug discovery and development, biological research, and as therapeutic implants for the treatment of damaged or degenerating tissues and organs.
HollySys Automation Technologies, Ltd. (NASDAQ:HOLI), ended its Wednesday’s trading session with 10.32% gain, and closed at $23.19, as on March 24, a leading provider of automation and control technologies and applications in China, declared that it has won a contract to provide its proprietary Distributed Control System for 2×1000MW ultra-supercritical thermal power generating units to Datang Sanmenxia Power Plant. The units are predictable to be placed into operation around September 2016.
The 2×1000MW ultra-supercritical thermal power generating units of Datang Sanmenxia Power Plant is a key project in Henan Province, which is funded and constructed by China Datang Corporation. In this project, Hollysys’ DCS will control more than 25,000 points and the ProfiBus will control over 4,500 distributed devices for the two GW level generating units. In addition, the HAMS (HolliAS Asset Administration System) perform as a central platform which is easy to integrate with other systems such as SIS, ERP, and MES.
Hollysys Automation Technologies Ltd. provides automation and control technologies and products to customers in industrial, railway, subway, nuclear power, building retrofit, and mechanical and electronic industries primarily in the People’s Republic China, Hong Kong, Southeast Asia, and the Middle East.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
